Skip to content
Open access

Safety, Efficacy, and Pharmacokinetics of Agalsidase Alfa in Treatment-Naive Chinese Patients with Fabry Disease: 52-Week Phase 3, Open-Label, Single-Arm Study.

Oct 2026 · Advances in Therapy · 0 citations · 20 references
Medicine

TL;DR

Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease and safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations.

Abstract

INTRODUCTION Clinical data on the efficacy, tolerability, and pharmacokinetics of agalsidase alfa in Chinese patients with Fabry disease are limited. We evaluated the safety, efficacy, and pharmacokinetics of agalsidase alfa in Chinese patients who are treatment-naive over 52 weeks.

Methods

This was an open-label, non-randomized, single-arm, multicenter (six centers in China) phase 3 study. Patients with Fabry disease (aged 7-65 years; either sex) received agalsidase alfa 0.2 mg/kg intravenously (every other week for up to 52 weeks). The primary endpoint was the incidence of serious treatment-emergent adverse events (TEAEs). Secondary endpoints included the incidence of TEAEs, changes from baseline in estimated glomerular filtration rate (eGFR), left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF), and agalsidase alfa pharmacokinetics.

Results

Overall, 20 patients were enrolled (May 2022 to January 2024) and received ≥ 1 dose of agalsidase alfa. The median number of infusions was 27; median exposure duration was 12.0 months. Agalsidase alfa was generally well tolerated. Two patients (10.0%) reported one serious TEAE each (sepsis, ectopic pregnancy). All patients reported ≥ 1 TEAE, most of which were mild or moderate (98.2%); nine patients (45.0%) had ≥ 1 TEAE assessed as related to treatment. Baseline eGFR, LVMI, and LVEF were 118.8 (21.4) mL/min/1.73 m2, 38.0 (11.2) g/m2.7, and 66.8% (4.9), respectively. Renal function and cardiac structure and function remained relatively stable over 52 weeks; mean (SD) changes in eGFR, LVMI, and LVEF from baseline were 4.1 (12.5) mL/min/1.73 m2, 0.56 (8.71) g/m2.7, and 0.8% (3.3%), respectively. Agalsidase alfa exposure (area under the concentration-time curve and maximum serum concentration) was generally similar at week 0 and at week 28.

Conclusions

Data from this 52-week study support the use of agalsidase alfa as a long-term treatment option for Chinese patients with Fabry disease. Safety, efficacy, and pharmacokinetic profiles were consistent with studies in other populations. Graphical Abstract available for this article. CLINICALTRIALS GOV ID NCT04974749.

Read PDF

Similar papers

Open access Oct 2026

Real-World Safety and Effectiveness of Cladribine Tablets in Older (≥ 50 Years) Patients with Relapsing Multiple Sclerosis: Results from the "Aging" Study-A Multicenter, Single-Arm, Phase 4 Observational Study.

INTRODUCTION Older patients with relapsing multiple sclerosis (PwRMS) are often underrepresented in clinical trials, limiting evidence on the safety and effectiveness of disease-modifying therapies. This study characterized the safety and effectiveness of short-course treatment with cladribine tablets (CladT) over 24 m...

J. Katz, Amy Gutierrez, L. Goldstick et al. · 0 citations
Open access Oct 2026

Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study

ICP-332 is a novel, orally administered TYK2 inhibitor with high selectivity, intended for the treatment of immune inflammatory diseases such as atopic dermatitis, psoriatic arthritis, inflammatory bowel disease and lupus. This Phase I study assessed its safety, pharmacokinetics, pharmacodynamics, and food effect i...

Heng-Li Zhao, Yi-Lin Wei, Yu Jiang et al. · 0 citations
Open access Nov 2026

Efficacy and safety of ofatumumab in Chinese participants with multiple sclerosis: results from a 12-month, prospective, open-label, multicenter study

Ofatumumab, a fully human anti-CD20 monoclonal antibody, has shown superior efficacy and a comparable overall safety profile to teriflunomide in the pivotal ASCLEPIOS I/II trials in people living with relapsing multiple sclerosis (plwRMS). However, data on the efficacy and safety of ofatumumab, a high-efficacy th...

Dong-Mei Jia, Hua-Bing Wang, Mei-Ni Zhang et al. · 0 citations
Oct 2026

Efficacy and safety of eculizumab in patients with anti-glomerular basement membrane disease: an investigator-initiated, open-label, phase II clinical trial.

BACKGROUND Anti-glomerular basement membrane disease (GBM) is the most severe type of autoimmune kidney diseases, and is associated with the overactivation of the complement cascade. We aimed to evaluate the efficacy and safety of eculizumab, a complement C5 blocker that targets terminal pathways, in patients with anti...

Huang Kuang, Xiao-Yu Jia, Pei Chen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.